From If You’ve Got a Real Breakthrough, the FDA Wants To Talk:

Hughes_T-2

Hughes_T-2—

Tom Hughes, CEO of Zafgen. Photo courtesy of Zafgen

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Sponsored · Video
The Importance of Early Planning for Biotechs & Engaging with a CRO for Molecule Development
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace

Sponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
CMC in Drug Development and Life Cycle Management
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!